DiscoverScience Will Win
Science Will Win
Claim Ownership

Science Will Win

Author: Pfizer

Subscribed: 44,285Played: 60,598
Share

Description

Science Will Win is a podcast that takes listeners under the microscope of some of the most promising medical innovations, exploring therapies that have the potential to shape the future of healthcare and offer new hope to patients around the world. Through conversations with a diverse line-up of guests, including scientists and experts, patient advocates, and, most importantly, patients themselves, each miniseries will focus on a unique healthcare challenge, diving into the fascinating science, policy challenges, and potential to transform patients’ lives for the better.

This podcast is powered by Pfizer.
14 Episodes
Reverse
Is it possible to live in a world without antibiotic resistant bacteria? For the final episode of this season, we’re looking ahead to the future and getting a glimpse of a potential world in which we stay one step ahead of AMR, and what is helping us get there. Host Jeremiah Owyang and expert guests will talk about the education, surveillance, and policy efforts needed for success in the fight against antibiotic resistant bacteria. And we’ll explore how artificial intelligence can empower us in those efforts — and enable more effective, accessible, and equitable healthcare.Featured Guests:Dame Sally Davies, UK Special Envoy for Antimicrobial ResistanceDaniel Gallego, President of the European Kidney Patient FederationRanjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, PfizerSubha Madhavan, Vice President & Head of AI/ML, Quantitative & Digital Sciences, Global Biometrics & Data ManagementJay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Artificial intelligence has the power to transform the way researchers study bacteria and develop new treatments – and we’re already seeing the benefits in healthcare. In part three, host Jeremiah Owyang and expert guests shed light on how AI expedites and enhances analyses, revolutionizing the search for new antibiotics. The benefits of AI extend to analyzing bacterial DNA, uncovering vulnerabilities, and potentially predicting bacterial evolution. This innovative technology aids scientists in pinpointing the most promising antibiotic candidates from a sea of possibilities and helps to streamline drug development.Featured Guests:Adrian Egli, Director, Institute of Medical Microbiology, University of ZurichLei Zhang, Executive Director of Medicinal Chemistry, Pfizer Medicine DesignMarinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Artificial intelligence could be an essential tool in the fight against antibiotic resistant bacteria – and data is a key part of developing that tool. In part two of this four-part series, expert guests break down the mechanics behind artificial intelligence and machine learning. As host Jeremiah Owyang traces the evolution of these tools in healthcare, he highlights the crucial role of data for understanding the problem of antibiotic resistance. Featured Guests:Adrian Egli, Director, Institute of Medical Microbiology, University of ZurichRanjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, PfizerMarinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Medicine’s struggle with antibiotic resistant bacteria is reaching a crisis point. In part one of this four-part series, host Jeremiah Owyang and expert guests delve into the world of antibiotics, exploring their history, the rise of antibiotic resistance, and the story of a patient whose life was forever changed by antibiotic-resistant bacteria. They break down the critical issues at stake and discuss the multifaceted solutions needed to combat this pressing crisis – including artificial intelligence.Featured Guests:Adrian Egli, Director, Institute of Medical Microbiology, University of ZurichJay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal ProgramsMary Lynne Van Poelgeest-Pomfret, President, World Federation of Incontinence and Pelvic Problems Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win is exploring how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. This season, we’ll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance. Tune in to this new, four-part series, coming soon!Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Oncologists have more innovative methods for treating breast cancer than ever before. In part one of this two-part series, Adam Rutherford and guests explore the hurdles and successes researchers face as they work to develop new, targeted therapies for breast cancer.Featured Guests:Martha Carlson, Breast Cancer Advocate & WriterDr. Edith Mitchell, Medical Oncologist, Thomas Jefferson UniversityJeff Settleman, Chief Scientific Officer, Pfizer Oncology
In part two of this series, Adam Rutherford and guests break down the next step in how potential breast cancer treatments move forward from the lab. What role do clinical trials play in the development of potential treatments? How are clinical trials developed? How can patients access clinical trials? And how are researchers and advocacy groups working to break down barriers in access to clinical trials?Featured Guests:Laurie, Breast Cancer Clinical Trial ParticipantDr. Edith Mitchell, Medical Oncologist, Thomas Jefferson UniversityJulia Perkins Smith, Global Clinical Lead, PfizerJamil Rivers, CEO, Chrysalis InitiativeAdditional Resources:pfizerclinicaltrials.com/oncologypfizerclinicaltrials.compfizerestudiosclinicos.com
Host Adam Rutherford returns to explore breakthroughs in oncology, the study and treatment of cancer, and more specifically breast cancer. We’ll hear from the scientists tasked with developing new treatments, oncologists who lead clinical trials and treat patients, and the patients and patient advocates themselves. It’s a groundbreaking time for cancer research, with as many promising possibilities as there are challenges to overcome. Tune in to this new, two-part series, launching October 27, 2022!
In this special bonus episode, Adam Rutherford explores a different aspect of gene therapy - how do you actually make one? Expert guests discuss the highly complex task of scaling-up manufacturing from the small amounts needed for research, to creating batches big enough for clinical and commercial scale. And once that hurdle has been cleared, how do they address the additional challenge of storing and transporting the medicine at ultra-low temperatures?Featuring guests:Bert Bruce, Regional President, North America, Rare Disease, PfizerBob Smith, Senior Vice President, Global Gene Therapy Business, Rare Disease, Pfizer Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer
Gene therapy is at a pivotal moment. For eligible rare disease patients, the potential impact could be huge. So how can we support that potential to fruition and what will it mean if we do? In our season finale, host Adam Rutherford and guests take a peek into what a world with successful gene therapies could look like for patients, healthcare and society.Featuring guests:Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare DisordersErik Paulsen, Chair, Institute for Gene TherapiesKarolina Hanslik, Former Senior Project Manager, EURORDISNikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, PfizerPaige Bischoff, Senior Vice President, Global Public Affairs,  Alliance for Regenerative MedicinePaolo Morgese, EU Director, Market Access, Alliance for Regenerative MedicineReda Guiha, IDM Regional President, Rare Disease, PfizerSimone Boselli, Director, Public Affairs, EURORDISTomislav Sokol, Member of European Parliament
The Policy Puzzle

The Policy Puzzle

2021-10-2228:564

As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them.Featuring guests:Bert Bruce, Regional President, North America, Rare Disease, Pfizer Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, PfizerDurhane Wong-Rieger, President & CEO at Canadian Organization for Rare DisordersEmily Crossley, Chief Executive Officer, Duchenne UKErik Paulsen, Chair, Institute for Gene TherapiesKarolina Hanslik, Senior Project Manager, EURORDISKatherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, PfizerNikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, PfizerSuneet Varma, Global President, Rare Disease, PfizerTomislav Sokol, Member of European Parliament 
Gene therapy has come a long way to get where it is today but there is still much to learn and investigate. Host Adam Rutherford speaks to a line-up of experts about the vital role of clinical trials and the unique challenges facing gene therapy and rare disease patients.Featuring guests:Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, PfizerEmily Crossley, Chief Executive Officer, Duchenne UKErik Paulsen, Chair, Institute for Gene TherapiesProfessor John Rasko, Clinical Haematologist & Trial Investigator, University of SydneySimone Boselli, Director, Public Affairs, EURORDISSuneet Varma, Global President, Rare Disease, Pfizer 
Gene therapy is a revolutionary field of science that has the potential to transform lives. It presents this big question; What if we could treat a disease at its root cause, rather than just the symptoms? On the first episode of Science Will Win, host Adam Rutherford takes us through the history, science, and significance of gene therapy.Featuring guests:Dirk Vander Mijnsbrugge, Vice President, Medical Affairs, Rare Diseases, PfizerDurhane Wong-Rieger, President & CEO at Canadian Organization for Rare DisordersLaurence Woollard, Director, On The Pulse ConsultancySonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer 
Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better. Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases. At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy. 
Comments (17)

Even J

🤔

Dec 17th
Reply

Rouzman Dallin

Greffe de Cheveux istanbul https://www.hairtimeistanbul.com/fr/

Mar 14th
Reply

Alireza Mohammadi

the.s good language ant English with the new one is

Dec 31st
Reply

Run 3

A disease that has existed for https://lolbeans.online decades, even now and in the future, there is still no cure. Can only be autonomous in the movie =)).

Dec 28th
Reply

Mahsa Hokmabadi

it's so interesting, can I promise you put the transcript file for international student in this field, it's help us to underestand better

Dec 25th
Reply (1)

Petison Weriosin

If you are thinking about a one-way open relationship and if you want to have a very high-quality and good experience, then I recommend you to look at this site https://mobidate.net/ . Since the average is very useful other information and articles here is also an article on this topic that will help you.

Dec 24th
Reply

Standivided

Nice channel ❤️

Dec 20th
Reply

Mike Boudet

Propaganda in Podcast Form

Jan 23rd
Reply

Joel Smith

I believe anything Pfizer says and i will inject anything into myself as long as it’s a big pharma ceo saying I need it

Dec 19th
Reply (2)

Daryl Smith

it might if you stop ignoring it when it's convenient

Oct 30th
Reply

Jacqueline K

The science is interesting and the potential is huge. The podcast is created by a pharmaceutical company that believes that for profit medical systems are ethical. All that makes this an interesting listen.

Oct 21st
Reply

Old man

one subject I think could be interesting is amateur gene hackers.

Oct 19th
Reply (2)
Download from Google Play
Download from App Store